Review of the quinolone family

Antibiotic Discovery and Development

Volumn , Issue , 2014, Pages 119-146

  Jacoby, George A ^a   Hooper, David C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929572155     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-1400-1_4     Document Type: Chapter

References (216)

1. Abrahamian FM, Talan DA, Moran GJ (2008) Management of skin and soft-tissue infections in the emergency department. Infect Dis Clin North Am 22:89-116, vi
2. Allou N, Cambau E, Massias L, Chau F, Fantin B (2009) Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother 53:4292-4297
3. Alonso A, Martinez JL (2000) Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 44:3079-3086
4. Alovero FL, Pan XS, Morris JE, Manzo RH, Fisher LM (2000) Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob Agents Chemother 44:320-325
5. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF (2001) Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 45: 2793-2797
6. Arredondo JL, Diaz V, Gaitan H et al (1997) Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin Infect Dis 24:170-178
7. Arsène S, Leclercq R (2007) Role of a qnr -like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. Antimicrob Agents Chemother 51:3254-3258
8. Aspinall SL, Good CB, Jiang R, McCarren M, Dong D, Cunningham FE (2009) Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis 49:402-408
9. Ball P (2000) Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 45:557-559
10. Ball P (2003) Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 51(Suppl 1):21-27
11. Ball P, Mandell L (2003) Treatment of community-acquired respiratory tract infections. In: Hooper DC, Rubinstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Washington, D.C
12. Barberán J, Aguilar L, Carroquino G et al (2006) Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med 119(993):e997-910
13. Barberán J, Aguilar L, Giménez MJ, Carroquino G, Granizo JJ, Prieto J (2008) Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation. Int J Antimicrob Agents 32:154-157
14. Barnard FM, Maxwell A (2001) Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser 83 and Asp 87. Antimicrob Agents Chemother 45:1994-2000
15. Bartlett JG, Inglesby TV Jr, Borio L (2002) Management of anthrax. Clin Infect Dis 35:851-858
16. Bennish ML (2003) Treatment and prophylaxis of gastroenteritis. In: Hooper DC, Rubinstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Washington, D.C
17. Berry A, Barratt A (2002) Prophylactic antibiotic use in transurethral prostatic resection: a meta-analysis. J Urol 167:571-577
18. Biering-Sorensen F, Høiby N, Nordenbo A, Ravnborg M, Bruun B, Rahm V (1994) Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. J Urol 151:105-108
19. Blázquez Garrido RM, Espinosa Parra FJ, Alemany Francés L et al (2005) Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis 40:800-806
20. Blum MD, Graham DJ, McCloskey CA (1994) Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 18:946-950
21. Bouza E, Díaz-López MD, Bernaldo de Quirós JC, Rodríguez-Créixems M (1989) Ciprofloxacin in patients with bacteremic infections. The Spanish Group for the Study of Ciprofloxacin. Am J Med 87:228S-231S
22. Bratu S, Landman D, George A, Salvani J, Quale J (2009) Correlation of the expression of acrB and the regulatory genes marA, soxS and ramA with antimicrobial resistance in clinical isolates of Klebsiella pneumoniae endemic to New York City. J Antimicrob Chemother 64:278-283
23. Cagnacci S, Gualco L, Debbia E, Schito GC, Marchese A (2008) European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J Clin Microbiol 46:2605-2612
24. Cattaneo C, Quaresmini G, Casari S et al (2008) Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 61:721-728
25. Cattoir V, Poirel L, Mazel D, Soussy CJ, Nordmann P (2007) Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. Antimicrob Agents Chemother 51:2650-2651
26. Cattoir V, Nordmann P (2009) Plasmid-mediated quinolone resistance in gram-negative bacterial species: an update. Curr Med Chem 16:1028-1046
27. Chan CC, Oppenheim BA, Anderson H, Swindell R, Scarffe JH (1989) Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother 33:87-91
28. Chau TT, Campbell JI, Galindo CM et al (2007) Antimicrobial drug resistance of Salmonella enterica serovar Typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 51:4315-4323
29. Chen HJ, Bloch KJ, Maclean JA (2000) Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med 342:359-360
30. Chen S, Cui S, McDermott PF et al (2007) Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. Antimicrob Agents Chemother 51:535-542
31. Chenia HY, Pillay B, Pillay D (2006) Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J Antimicrob Chemother 58:1274-1278
32. Chocarro A, Gonzalez A, Garcia I (2000) Treatment of tularemia with ciprofloxacin. Clin Infect Dis 31:623
33. Chrysanthopoulos CJ, Skoutelis AT, Starakis JC, Arvaniti A, Bassaris HP (1988) Use of ciprofloxacin in biliary sepsis. Infection 16:249
34. Chu YW, Cheung TK, Ng TK et al (2006) Quinolone resistance determinant qnrA3 in clinical isolates of Salmonella in 2000-2005 in Hong Kong. J Antimicrob Chemother 58:904-905
35. Chuang CH, Su LH, Perera J et al (2009) Surveillance of antimicrobial resistance of Salmonella enterica serotype Typhi in seven Asian countries. Epidemiol Infect 137: 266-269
36. Courvalin P (1990) Plasmid-mediated 4-quinolone resistance: a real or apparent absence? Antimicrob Agents Chemother 34:681-684
37. Covino JM, Black JR, Cummings M, Zwickl B, McCormack WM (1993) Comparative evaluation of ofloxacin and metronidazole in the treatment of bacterial vaginosis. Sex Transm Dis 20:262-264
38. Craig WA, Andes DR (2003) Pharmacodynamics of quinolone antimicrobial agents. In: Hooper DC, Rubinstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Washington, D.C
39. Crombleholme WR, Schachter J, Ohm-Smith M, Luft J, Whidden R, Sweet RL (1989) Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. Am J Med 87:142S-147S
40. Dalhoff A, Weidner W (1988) Diffusion of ciprofloxacin into prostatic fluid. Eur J Clin Microbiol Infect Dis 7:438-439
41. Dalhoff A, Schmitz FJ (2003) In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 22:203-221
42. Davidson R, Cavalcanti R, Brunton JL et al (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346:747-750
43. Defife R, Scheetz MH, Feinglass JM, Postelnick MJ, Scarsi KK (2009) Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gramnegative organisms treated with levofloxacin. Antimicrob Agents Chemother 53:1074-1079
44. Del Pozo JL, Patel R (2009) Infection associated with prosthetic joints. N Engl J Med 361:787-794
45. Dong KC, Berger JM (2007) Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature 450:1201-1205
46. Dow G, Rao P, Harding G et al (2004) A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury. Clin Infect Dis 39:658-664
47. Drlica K, Zhao X (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Molec Biol Rev 61:377-392
48. Drlica K (2003) The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52:11-17
49. Drlica K, Hooper DC (2003) Mechanisms of quinolone action. In: Hooper DC, Rubinstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Washington, D.C
50. Drlica K, Malik M, Kerns RJ, Zhao X (2008) Quinolone-mediated bacterial death. Antimicrob Agents Chemother 52:385-392
51. Duesberg CB, Malhotra-Kumar S, Goossens H et al (2008) Interspecies recombination occurs frequently in quinolone resistance-determining regions of clinical isolates of Streptococcus pyogenes. Antimicrob Agents Chemother 52:4191-4193
52. Dutta D, Bhattacharya SK, Bhattacharya MK et al (1996) Efficacy of norfloxacin and doxycycline for treatment of Vibrio cholerae 0139 infection. J Antimicrob Chemother 37: 575-581
53. Dworkin RJ, Lee BL, Sande MA, Chambers HF (1989) Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 2:1071-1073
54. Eaves DJ, Ricci V, Piddock LJ (2004) Expression of acrB, acrF, acrD, marA, and soxS in Salmonella enterica serovar Typhimurium: role in multiple antibiotic resistance. Antimicrob Agents Chemother 48:1145-1150
55. Edelstein PH (1998) Antimicrobial chemotherapy for Legionnaires disease: time for a change. Ann Intern Med 129:328-330
56. Edgar R, Bibi E (1997) MdfA, an Escherichia coli multidrug resistance protein with an extraordinarily broad spectrum of drug recognition. J Bacteriol 179:2274-2280
57. Ericsson CD, Johnson PC, Dupont HL, Morgan DR, Bitsura JA, de la Cabada FJ (1987) Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial. Ann Intern Med 106:216-220
58. Ericsson CD, DuPont HL, Mathewson JJ (1997) Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of traveler's diarrhea. J Travel Med 4:3-7
59. Fang GD, Brennen C, Wagener M et al (1991) Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother 35:1849-1855
60. Ferran AA, Kesteman AS, Toutain PL, Bousquet-Melou A (2009) Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model. Antimicrob Agents Chemother 53:3384-3390
61. Feuerriegel S, Heisig P (2008) Role of global regulator Rma for multidrug efflux-mediated fluoroquinolone resistance in Salmonella. Microb Drug Resist 14:259-263
62. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073-1081
63. Fourcroy JL, Berner B, Chiang YK, Cramer M, Rowe L, Shore N (2005) Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother 49: 4137-4143
64. Fournier B, Aras R, Hooper DC (2000) Expression of the multidrug resistance transporter NorA from Staphylococcus aureus is modified by a two-component regulatory system. J Bacteriol 182:664-671
65. Fu Y, Guo L, Xu Y et al (2008) Alteration of GyrA amino acid required for ciprofloxacin resistance in Klebsiella pneumoniae isolates in China. Antimicrob Agents Chemother 52:2980-2983
66. Gellert M, Mizuuchi K, O'Dea MH, Nash HA (1976) DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci USA 73:3872-3876
67. Gellert M, O'Dea MH, Itoh T, Tomizawa J (1976) Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc Natl Acad Sci U S A 73:4474-4478
68. Gentry LO (1991) Oral antimicrobial therapy for osteomyelitis. Ann Intern Med 114: 986-987
69. Gentry LO (1991b) Review of quinolones in the treatment of infections of the skin and skin structure. J Antimicrob Chemother 28(Suppl C):97-110
70. Giamarellou H, Kolokythas E, Petrikkos G, Gazis J, Aravantinos D, Sfikakis P (1989) Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med 87:49S-51S
71. Gill MJ, Brenwald NP, Wise R (1999) Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 43:187-189
72. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S (2005) Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 26:357-365
73. Giraud E, Cloeckaert A, Baucheron S, Mouline C, Chaslus-Dancla E (2003) Fitness cost of fluoroquinolone resistance in Salmonella enterica serovar Typhimurium. J Med Microbiol 52:697-703
74. Gisbert JP, Fernandez-Bermejo M, Molina-Infante J et al (2007) First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 26:495-500
75. Gisbert JP, Bermejo F, Castro-Fernandez M et al (2008) Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 103:71-76
76. Gómez-Jiménez J, Ribera E, Almirante B, Del Valle O, Pahissa A, Martínez-Vázquez JM (1989) Ciprofloxacin resistance and staphylococcal endocarditis. Lancet 334:1525-1526
77. Gotuzzo E, Seas C, Echevarria J, Carrillo C, Mostorino R, Ruiz R (1995) Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin Infect Dis 20:1485-1490
78. Graham DR, Talan DA, Nichols RL et al (2002) Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 35:381-389
79. Greenberg RN, Newman MT, Shariaty S, Pectol RW (2000) Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob Agents Chemother 44:164-166
80. Grosset JH, Ji BH, Guelpa-Lauras CC, Perani EG, N'Deli LN (1990) Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis 58:281-295
81. Grosset JH (2001) Newer drugs in leprosy. Int J Lepr Other Mycobact Dis 69:S14-18
82. Gupta K, Naber K, Stamm W (2003) Treatment of urinary tract infections. In: Hooper DC, Rubinstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Washington, D.C
83. Hansen LH, Jensen LB, Sorensen HI, Sorensen SJ (2007) Substrate specificity of the OqxAB multidrug resistance pump in Escherichia coli and selected enteric bacteria. J Antimicrob Chemother 60:145-147
84. Healy DP, Brodbeck MC, Clendening CE (1996) Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother 40:6-10
85. Heaton VJ, Ambler JE, Fisher LM (2000) Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob Agents Chemother 44:3112-3117
86. Hegde SS, Vetting MW, Roderick SL et al (2005) A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science 308:1480-1403
87. Heldman AW, Hartert TV, Ray SC et al (1996) Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 101:68-76
88. Hooper DC (2003) Mechanisms of quinolone resistance. In: Hooper DC, Rubinstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Washington, D.C
89. Hussy P, Maass G, Tummler B, Grosse F, Schomburg U (1986) Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother 29:1073-1078
90. Jacobs MR (2004) Fluoroquinolones as chemotherapeutics against mycobacterial infections. Curr Pharm Des 10:3213-3220
91. Jacoby G, Cattoir V, Hooper D et al (2008) qnr gene nomenclature. Antimicrob Agents Chemother 52:2297-2299
92. Jacoby GA (2005) Mechanisms of resistance to quinolones. Clin Infect Dis 41(Suppl 2): S120-126
93. Jacoby GA, Walsh KE, Mills DM et al (2006) qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob Agents Chemother 50:1178-1182
94. Jacoby GA, Gacharna N, Black TA, Miller GH, Hooper DC (2009) Temporal appearance of plasmid-mediated quinolone resistance genes. Antimicrob Agents Chemother 53: 1665-1666
95. Jansen J, Cromer M, Akard L, Black JR, Wheat LJ, Allen SD (1994) Infection prevention in severely myelosuppressed patients: a comparison between ciprofloxacin and a regimen of selective antibiotic modulation of the intestinal flora. Am J Med 96:335-341
96. Jellen-Ritter AS, Kern WV (2001) Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants selected with a fluoroquinolone. Antimicrob Agents Chemother 45:1467-1472
97. Kaatz GW, McAleese F, Seo SM (2005) Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. Antimicrob Agents Chemother 49:1857-1864
98. Kampranis SC, Bates AD, Maxwell A (1999) A model for the mechanism of strand passage by DNA gyrase. Proc Natl Acad Sci USA 96:8414-8419
99. Karchmer AW (2003) Treatment off skin and soft tissue infections. In: Hooper DC, Rubinstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Washington, D.C
100. Kato J, Nishimura Y, Imamura R, Niki H, Hiraga S, Suzuki H (1990) New topoisomerase essential for chromosome segregation in E. coli. Cell 63:393-404
101. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 341:312-318
102. Kim HB, Wang M, Park CH, Kim EC, Jacoby GA, Hooper DC (2009) oqxAB encoding a multidrug efflux pump in human clinical isolates of Enterobacteriaceae. Antimicrob Agents Chemother 53:3582-3584
103. Kitchen VS, Donegan C, Ward H, Thomas B, Harris JR, Taylor-Robinson D (1990) Comparison of ofloxacin with doxycycline in the treatment of non-gonococcal urethritis and cervical chlamydial infection. J Antimicrob Chemother 26(Suppl D):99-105
104. Ko WC, Hsueh PR (2009) Increasing extended-spectrum b-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: Data from the Smart Study 2002-2006. J Infect 59(2):95-103
105. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC (1997) Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 23:345-354
106. Komp Lindgren P, Karlsson A, Hughes D (2003) Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 47:3222-3232
107. Laponogov I, Sohi MK, Veselkov DA et al (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol 16:667-669
108. Le TP, Yeaman MR, Bayer AS (2003) Treatment of experimental and human bacterial endocarditis with quinolone antimicrobial agents. In: Hooper DC, Rubinstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Washington, D.C
109. Lee BL, Padula AM, Kimbrough RC et al (1991) Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 325:520-521
110. Limaye AP, Hooper CJ (1999) Treatment of tularemia with fluoroquinolones: two cases and review. Clin Infect Dis 29:922-924
111. Lipsky BA, Tack KJ, Kuo CC, Wang SP, Grayston JT (1990) Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am J Med 89:722-724
112. Low DE (2004) Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin Infect Dis 38(Suppl 4):S357-362
113. Lutters M, Vogt-Ferrier NB (2008) Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst Rev Issue 3, vol. No. CD001535
114. Malik M, Zhao X, Drlica K (2006) Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Mol Microbiol 61:810-825
115. Mandell LA, Wunderink RG, Anzueto A et al (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27-72
116. Marcusson LL, Frimodt-Møller N, Hughes D (2009) Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 5:e1000541
117. Martinez-Martinez L, Eliecer Cano M, Manuel Rodriguez-Martinez J, Calvo J, Pascual A (2008) Plasmid-mediated quinolone resistance. Expert Rev Anti Infect Ther 6:685-711
118. Martínez-Martínez L, Pascual A, Jacoby GA (1998) Quinolone resistance from a transferable plasmid. Lancet 351:797-799
119. Martínez-Martínez L, Pascual A, García I, Tran J, Jacoby GA (2003) Interaction of plasmid and host quinolone resistance. J Antimicrob Chemother 51:1037-1039
120. Marutani K, Matsumoto M, Otabe Y et al (1993) Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light. Antimicrob Agents Chemother 37:2217-2223
121. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T (2000) Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44:3322-3327
122. Maurin M, Raoult D (1999) Q fever. Clin Microbiol Rev 12:518-553
123. Mazzariol A, Zuliani J, Cornaglia G, Rossolini GM, Fontana R (2002) AcrAB efflux system: expression and contribution to fluoroquinolone resistance in Klebsiella spp. Antimicrob Agents Chemother 46:3984-3986
124. Mérens A, Matrat S, Aubry A et al (2009) The pentapeptide repeat proteins MtMfpA and QnrB4 exhibit opposite rffects on DNA gyrase catalytic reactions and on the ternary gyrase- DNA-quinolone complex. J Bacteriol 191(5):1587-1594
125. Meunier F, Zinner SH, Gaya H et al (1991) Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother 35:873-878
126. Miehlke S, Schneider-Brachert W, Kirsch C et al (2008) One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 13:69-74
127. Mikamo H, Sato Y, Hayasaki Y, Hua YX, Tamaya T (2000) Adequate levofloxacin treatment schedules for uterine cervicitis caused by Chlamydia trachomatis. Chemotherapy 46: 150-152
128. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T (1999) Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob Agents Chemother 43:415-417
129. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F (2007) Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 67:2077-2099
130. Mombelli G, Pezzoli R, Pinoja-Lutz G, Monotti R, Marone C, Franciolli M (1999) Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med 159:53-58
131. Morais Cabral JH, Jackson AP, Smith CV, Shikotra N, Maxwell A, Liddington RC (1997) Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388:903-906
132. Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L (2009) Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 53:235-241
133. Morrison A, Cozzarelli NR (1979) Site-specific cleavage of DNA by E. coli DNA gyrase. Cell 17:175-184
134. Naamara W, Plummer FA, Greenblatt RM, D'Costa LJ, Ndinya-Achola JO, Ronald AR (1987) Treatment of chancroid with ciprofloxacin. A prospective, randomized clinical trial. Am J Med 82:317-320
135. Naber KG, Weidner W (2000) Chronic prostatitis-an infectious disease? J Antimicrob Chemother 46:157-161
136. Nakano M, Yasuda M, Yokoi S, Takahashi Y, Ishihara S, Deguchi T (2001) In vivo selection of Pseudomonas aeruginosa with decreased susceptibilities to fluoroquinolones during fluoroquinolone treatment of urinary tract infection. Urology 58:125-128
137. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP (2003) Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289:885-888
138. Newman LM, Moran JS, Workowski KA (2007) Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 44(Suppl 3):S84-101
139. Neyfakh AA, Borsch CM, Kaatz GW (1993) Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob Agents Chemother 37:128-129
140. Nicolle LE (2002) Urinary tract infection: traditional pharmacologic therapies. Am J Med 113(Suppl 1A):35S-44S
141. Niederman MS, Craven DE, Bonten MJ et al (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416
142. Nishino K, Yamaguchi A (2001) Analysis of a complete library of putative drug transporter genes in Escherichia coli. J Bacteriol 183:5803-5812
143. Ober MC, Hoppe-Tichy T, Koninger J et al (2009) Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections. J Antimicrob Chemother 64:1091-1095
144. Okumura R, Hoshino K, Otani T, Yamamoto T (2009) Quinolones with enhanced bactericidal activity induce autolysis in Streptococcus pneumoniae. Chemotherapy 55:262-269
145. Okusu H, Ma D, Nikaido H (1996) AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J Bacteriol 178:306-308
146. Ott SR, Allewelt M, Lorenz J, Reimnitz P, Lode H (2008) Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 36:23-30
147. Pan XS, Fisher LM (1998) DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother 42:2810-2816
148. Park-Wyllie LY, Juurlink DN, Kopp A et al (2006) Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354:1352-1361
149. Périchon B, Courvalin P, Galimand M (2007) Transferable resistance to aminoglycosides by methylation of G1405 in 16 S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob Agents Chemother 51:2464-2469
150. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB (2008) A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 71:17-22
151. Petruccelli BP, Murphy GS, Sanchez JL et al (1992) Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J Infect Dis 165:557-560
152. Pfau A, Sacks TG (1993) Single dose quinolone treatment in acute uncomplicated urinary tract infection in women. J Urol 149:532-534
153. Picão RC, Poirel L, Demarta A et al (2008) Plasmid-mediated quinolone resistance in Aeromonas allosaccharophila recovered from a Swiss lake. J Antimicrob Chemother 62: 948-950
154. Pierfitte C, Royer RJ (1996) Tendon disorders with fluoroquinolones. Therapie 51:419-420
155. Poirel L, Liard A, Rodriguez-Martinez JM, Nordmann P (2005) Vibrionaceae as a possible source of Qnr-like quinolone resistance determinants. J Antimicrob Chemother 56:1118-1121
156. Poirel L, Rodriguez-Martinez JM, Mammeri H, Liard A, Nordmann P (2005) Origin of plasmid- mediated quinolone resistance determinant QnrA. Antimicrob Agents Chemother 49:3523-3525
157. Polk RE, Healy DP, Sahai J, Drwal L, Racht E (1989) Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 33:1841-1844
158. Poole K, Krebes K, McNally C, Neshat S (1993) Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol 175:7363-7372
159. Poole K, Gotoh N, Tsujimoto H et al (1996) Overexpression of the mexC-mexD-oprJ efflux operon in nfxB -type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 21:713-724
160. Poole K (2000) Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria. Antimicrob Agents Chemother 44:2595-2599
161. Poole K (2000) Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother 44:2233-2241
162. Poole M, Anon J, Paglia M, Xiang J, Khashab M, Kahn J (2006) A trial of high-dose, shortcourse levofloxacin for the treatment of acute bacterial sinusitis. Otolaryngol Head Neck Surg 134:10-17
163. Preston SL, Drusano GL, Berman AL et al (1998) Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129
164. Radandt JM, Marchbanks CR, Dudley MN (1992) Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis 14:272-284
165. Raz R, Rottensterich E, Hefter H, Kennes Y, Potasman I (1989) Single-dose ciprofloxacin in the treatment of uncomplicated urinary tract infection in women. Eur J Clin Microbiol Infect Dis 8:1040-1042
166. Raz R, Rottensterich E, Leshem Y, Tabenkin H (1994) Double-blind study comparing 3-day regimens of cefixime and ofloxacin in treatment of uncomplicated urinary tract infections in women. Antimicrob Agents Chemother 38:1176-1177
167. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R (2002) Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 34:1469-1474
168. Regamey C, Steinbach-Lebbin C (1990) Severe infections treated with intravenous ofloxacin: a prospective clinical multicentre Swiss study. J Antimicrob Chemother 26(Suppl D): 107-114
169. Richard GA, Klimberg IN, Fowler CL, Callery-D'Amico S, Kim SS (1998) Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 52:51-55
170. Robicsek A, Jacoby GA, Hooper DC (2006) The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 6:629-640
171. Robicsek A, Strahilevitz J, Jacoby GA et al (2006) Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12:83-88
172. Rodríguez-Martínez JM, Velasco C, García I, Cano ME, Martínez-Martínez L, Pascual A (2007) Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1. Antimicrob Agents Chemother 51:2236-2239
173. Rodríguez-Martínez JM, Velasco C, Briales A, García I, Conejo MC, Pascual A (2008) Qnr-like pentapeptide repeat proteins in gram-positive bacteria. J Antimicrob Chemother 61:1240-1243
174. Rolain J-M, Raoult D (2003) Treatment of intracellular infections. In: Hooper DC, Rubinstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Washington, D.C
175. Ross JD, Cronje HS, Paszkowski T et al (2006) Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sex Transm Infect 82:446-451
176. Saga T, Kaku M, Onodera Y, Yamachika S, Sato K, Takase H (2005) Vibrio parahaemolyticus chromosomal qnr homologue VPA0095: demonstration by transformation with a mutated gene of its potential to reduce quinolone susceptibility in Escherichia coli. Antimicrob Agents Chemother 49:2144-2145
177. Salam I, Katelaris P, Leigh-Smith S, Farthing MJ (1994) Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. Lancet 344:1537-1539
178. Sánchez MB, Hernández A, Rodríguez-Martínez JM, Martínez-Martínez L, Martínez JL (2008) Predictive analysis of transmissible quinolone resistance indicates Stenotrophomonas maltophilia as a potential source of a novel family of Qnr determinants. BMC Microbiol 8:148-161
179. Sanchez P, Alonso A, Martinez JL (2002) Cloning and characterization of SmeT, a repressor of the Stenotrophomonas maltophilia multidrug efflux pump SmeDEF. Antimicrob Agents Chemother 46:3386-3393
180. Schaad UB, Wedgwood J (1992) Lack of quinolone-induced arthropathy in children. J Antimicrob Chemother 30:414-416
181. Schneiders T, Amyes SG, Levy SB (2003) Role of AcrR and ramA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore. Antimicrob Agents Chemother 47:2831-2837
182. Shafran SD, Singer J, Zarowny DP et al (1996) A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 335:377-383
183. Siegert R, Gehanno P, Nikolaidis P et al (2000) A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 94:337-344
184. Solomkin JS (2003) Treatment of inrra-abdominal infections. In: Hooper DC, Rubinstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Washington, D.C
185. Sorgel F, Kinzig M (1993) Pharmacokinetics of gyrase inhibitors, Part 2: Renal and hepatic elimination pathways and drug interactions. Am J Med 94:56S-69S
186. Stanhope MJ, Walsh SL, Becker JA et al (2005) Molecular evolution perspectives on intraspecific lateral DNA transfer of topoisomerase and gyrase loci in Streptococcus pneumoniae, with implications for fluoroquinolone resistance development and spread. Antimicrob Agents Chemother 49:4315-4326
187. Stanley PJ, Flegg PJ, Mandal BK, Geddes AM (1989) Open study of ciprofloxacin in enteric fever. J Antimicrob Chemother 23:789-791
188. Strahilevitz J, Hooper DC (2005) Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother 49:1949-1956
189. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A (2009) Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 22:664-689
190. Tamai I, Yamashita J, Kido Y et al (2000) Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther 295:146-152
191. Tran JH, Jacoby GA (2002) Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci U S A 99:5638-5642
192. Tran JH, Jacoby GA, Hooper DC (2005) Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob Agents Chemother 49: 3050-3052
193. Tran JH, Jacoby GA, Hooper DC (2005) Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother 49: 118-125
194. Truong-Bolduc QC, Dunman PM, Strahilevitz J, Projan SJ, Hooper DC (2005) MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol 187: 2395-2405
195. Truong-Bolduc QC, Strahilevitz J, Hooper DC (2006) NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob Agents Chemother 50:1104-1107
196. Tunkel AR, Scheld WM (2003) Treatment of bacterial meningitis and other central nervous system infections. In: Hooper DC, Rubinstein E (eds) Quinolone antimicrobial agents, 3rd edn. ASM Press, Wshington, D.C
197. Usubutun S, Agalar C, Diri C, Turkyilmaz R (1997) Single dose ciprofloxacin in cholera. Eur J Emerg Med 4:145-149
198. Wang F, Gu XJ, Zhang MF, Tai TY (1989) Treatment of typhoid fever with ofloxacin. J Antimicrob Chemother 23:785-788
199. Wang H, Dzink-Fox JL, Chen M, Levy SB (2001) Genetic characterization of highly fluoroquinolone- resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother 45:1515-1521
200. Wang JC (1998) Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q Rev Biophys 31:107-144
201. Wang M, Tran JH, Jacoby GA, Zhang Y, Wang F, Hooper DC (2003) Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother 47:2242-2248
202. Wang X, Zhao X (2009) Contribution of oxidative damage to antimicrobial lethality. Antimicrob Agents Chemother 53:1395-1402
203. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE (1999) Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 29:745-758
204. Willmott CJ, Maxwell A (1993) A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob Agents Chemother 37:126-127
205. Wistrom J, Jertborn M, Hedstrom SA et al (1989) Short-term self-treatment of travellers' diarrhoea with norfloxacin: a placebo-controlled study. J Antimicrob Chemother 23: 905-913
206. Wolf JS Jr, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ (2008) Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 179:1379-1390
207. Workowski KA, Berman SM (2006) Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 55:1-94
208. Wu HM, Harcourt BH, Hatcher CP et al (2009) Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med 360:886-892
209. Yamane K, Wachino J, Suzuki S et al (2007) New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother 51:3354-3360
210. Yang S, Clayton SR, Zechiedrich EL (2003) Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli. J Antimicrob Chemother 51:545-556
211. Yoshida H, Bogaki M, Nakamura M, Nakamura S (1990) Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 34: 1271-1272
212. Zhang L, Li XZ, Poole K (2000) Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother 44:287-293
213. Zhang L, Li XZ, Poole K (2001) SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 45:3497-3503
214. Zhao X, Drlica K (2001) Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33(Suppl 3):S147-S156
215. Zhao X, Drlica K (2008) A unified anti-mutant dosing strategy. J Antimicrob Chemother 62:434-436
216. Zheng J, Cui S, Meng J (2009) Effect of transcriptional activators RamA and SoxS on expression of multidrug efflux pumps AcrAB and AcrEF in fluoroquinolone-resistant Salmonella Typhimurium. J Antimicrob Chemother 63:95-102